Your browser doesn't support javascript.
loading
Gantenerumab for early Alzheimer's disease: a systematic review and meta-analysis.
Menegaz de Almeida, Artur; Leite, Marianna; Lopes, Lucca Moreira; Gomes Lima, Pedro; Siegloch Barros, Maria Luísa; Rocha Pinheiro, Samuel; Andrade, Ítalo; Viana, Patrícia; Morbach, Victória; Marinheiro, Gabriel; de Oliveira, Ricardo; Pinheiro, Agostinho C.
Afiliação
  • Menegaz de Almeida A; Department of Medicine, Federal University of Mato Grosso, Sinop, Brazil.
  • Leite M; Department of Medicine, Santa Marcelina University, São Paulo, Brazil.
  • Lopes LM; Department of Medicine, Sciences Medical School of Santos, Santos, Brazil.
  • Gomes Lima P; Department of Medicine, Federal University of Acre, Rio Branco, Brazil.
  • Siegloch Barros ML; Department of Medicine, Federal University of Acre, Rio Branco, Brazil.
  • Rocha Pinheiro S; Department of Medicine, Federal University of Bahia, Anísio Teixeira, Brazil.
  • Andrade Í; Department of Medicine, Santo Agostinho Faculty, Vitória da Conquista, Brazil.
  • Viana P; Department of Medicine, Extremo Sul University, Criciúma, Brazil.
  • Morbach V; Department of Medicine, Feevale University, Novo Hamburgo, Brazil.
  • Marinheiro G; Department of Medicine, Federal University of Ceará, Fortaleza, Brazil.
  • de Oliveira R; Institute of Health Sciences, Federal University of Mato Grosso, Sinop, Brazil.
  • Pinheiro AC; Department of Neurosciences, Behavioural Neurosciences Institute (INeC), Ribeirão Preto, Brazil.
Expert Rev Neurother ; 24(9): 929-936, 2024 Sep.
Article em En | MEDLINE | ID: mdl-38879828
ABSTRACT

INTRODUCTION:

Gantenerumab is a monoclonal antibody targeting amyloid ß protein (Aß) in early Alzheimer's disease (AD). The authors sought to evaluate gantenerumab safety and efficacy in early AD patients.

METHODS:

MEDLINE, Embase, and Cochrane databases were systematically searched until 2 December 2023. Data were examined using the Mantel-Haenszel method and 95% confidence intervals (CIs). Meta-regression analysis was conducted to evaluate a possible link between baseline Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) and amyloid-related imaging abnormalities (ARIA) at follow-up. R, version 4.2.3, was used for statistical analysis.

RESULTS:

A total of 4 RCTs and 2848 patients were included, of whom 1580 (55%) received subcutaneous gantenerumab. Concerning clinical scores, the placebo group achieved better rates of change in the Disease Assessment Scale (ADAS-Cog13) (SMD -0.11; 95% CI -0.19- -0.03; p = 0.008569; I2 = 0%). Gantenerumab was strongly associated with the occurrence of ARIA-E and ARIA-H (19.67% vs. 2.31%; RR 9.46; 95% CI 5.55-16.11; p = <0.000001; I2 = 10%) and (21.95% vs. 12.38%; RR 1.79; 95% CI 1.50-2.13; p = <0.000001; I2 = 0%), respectively.

DISCUSSION:

In this meta-analysis, consistent results suggest that gantenerumab is not safe and efficient for early AD, showing no improvement in clinical scores for AD and being associated with the occurrence of ARIA-E and ARIA-H.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Alzheimer / Anticorpos Monoclonais Humanizados Limite: Humans Idioma: En Revista: Expert Rev Neurother Assunto da revista: NEUROLOGIA / TERAPEUTICA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Alzheimer / Anticorpos Monoclonais Humanizados Limite: Humans Idioma: En Revista: Expert Rev Neurother Assunto da revista: NEUROLOGIA / TERAPEUTICA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido